Study summary
A progranulin-boosting pill was safe, with early signs of slower progression
What was tested
AZP2006, a once-daily pill that stabilizes progranulin (a protein that supports brain cell clean-up), at two doses against placebo for 12 weeks, plus a 6-month open-label extension.
What they found
- No treatment-related serious side effects.
- Biomarkers showed the drug reached the brain and engaged its target.
- Clinical trends favored slower progression, but the study was not designed to prove benefit.
What it means
Supports a larger trial.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.